Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations. 
X
Active Filter(s):
Details:
Company launched USFDA approved Venlafaxine Hydrochloride-Generic, an selective serotonin and norepinephrine reuptake inhibitors for the treatment of major depressive disorder, generalized anxiety disorder, panic disorder, and social phobia.
Lead Product(s): Venlafaxine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Venlafaxine Hydrochloride-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
